Skip to main content
27 FEBRUARY, 2019

bioMérieux – 2018 Financial Results

  • Organic sales growth of 9.9% for full-year 2018:
    • €2,421 million in sales
    • Up 5.8% as reported
    • Solid fourth-quarter performance, with organic growth of more than 10%
  • Improvement in contributive operating income before non-recurring items, which came to €361 million or close to 15% of sales, despite unfavorable currency effect
  • 2019 financial targets:
    • Organic growth in sales of between 7.0% and 8.5%, at constant exchange rates and scope of consolidation
    • Contributive operating income before non-recurring items of between €385 million and €400 million, at current exchange rates

Alexandre Mérieux, Chairman and Chief Executive Officer, said: “In 2018, bioMérieux recorded very satisfactory results and stepped up the deployment of its immunoassay strategy, with Astute and Hybiome transactions. In 2019, bioMérieux intends to maintain its sales dynamics and to improve its operational and financial performance, for the benefit of clients and patients, true to its continued commitment to serve public health."

471 KB